Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Obesity · 2025
DOI: 10.1002/oby.24160 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Obesity, 2025. Verfasst von Alissa S Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Weight Loss. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Objective
The objective of this study was to examine weight reduction and adverse events associated with use of antiobesity medications (AOMs) in older adults ages ≥65 years.
Methods
Seven databases were searched for studies evaluating weight reduction of Food and Drug Administration (FDA)‐approved AOMs. Studies had to include adults ages ≥65 years with obesity (BMI ≥ 30 kg/m 2 or ≥27 kg/m 2 with one weight‐related condition), with independent analysis of weight reduction for adults ages ≥65 years. Two coauthors extracted and evaluated studies for risk of bias using standardized forms.
Results
Six experimental studies (five secondary analyses of randomized clinical trial data and one single‐arm trial) and two observational studies met inclusion criteria. Seven medications were studied. Sample size of older adults ranged from 13 to 6728. Experimental studies predominantly included patients with concurrent prediabetes or cardiovascular disease. All studies found statistically significant weight reduction between intervention and placebo groups or compared with baseline weight. Few studies reported on adverse events.
Conclusions
Limited evidence suggests weight reduction of AOMs in older adults, with the best current evidence for the use of semaglutide in older adults with obesity and cardiovascular disease. Larger, more inclusive studies of older adults are needed to guide clinical care and determine the tolerability of AOMs for older adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, Connecticut, USA.
- Yale Obesity Research Center (Y-Weight), Yale School of Medicine, New Haven, Connecticut, USA.
- Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut, USA.
ORCID-Profile: Alissa S Chen, Ania M Jastreboff
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Chen, A. S., Hajduk, A. M., Grimshaw, A. A., Fried, T. R., Jastreboff, A. M., & Lipska, K. J. (2025). Efficacy of antiobesity medications for weight reduction in older adults: a systematic review. Obesity. https://doi.org/10.1002/oby.24160
Vancouver
Chen AS, Hajduk AM, Grimshaw AA, Fried TR, Jastreboff AM, Lipska KJ. Efficacy of antiobesity medications for weight reduction in older adults: a systematic review. Obesity. 2025. doi:10.1002/oby.24160
BibTeX
@article{Chen2025,
author = {Chen, Alissa S and Hajduk, Alexandra M and Grimshaw, Alyssa A and Fried, Terri R and Jastreboff, Ania M and Lipska, Kasia J},
title = {Efficacy of antiobesity medications for weight reduction in older adults: a systematic review},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24160}
}
EUVIMED